Skip to main content
. 2020 Feb 16;177(6):1434–1452. doi: 10.1111/bph.14912

Figure 3.

Figure 3

Icariside II (ICS II) mitigates expression and activity of PDE 5 and increased cerebral I/R‐induced cGMP level and PKG activity in penumbra. (a) PDE 5A expression at Day 3. (b) Quantitation of PDE 5A at Day 3 (n = 5 per group). (c) PDE 5A expression at Day 7. (d) Quantitation of PDE 5A at Day 7 (n = 5 per group). (e) PDE 5 activity at Day 3. (f) cGMP level at Day 3 (n = 5 per group). (g) PKG activity at Day 3 (n = 5 per group). (h) PDE 5 activity at Day 7 (n = 5 per group). (i) cGMP level at Day 7 (n = 5 per group). (j) PKG activity at Day 7 (n = 5 per group). The data were presented as the mean ± SEM. *P < .05 versus sham group; # P < .05 versus MCAO group